Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSIW) Depreciation & Amortization (CF) (2022 - 2026)

TriSalus Life Sciences posted quarterly Depreciation & Amortization (CF) of $135000.0 for Q1 2026, down 21.51% year-on-year from $172000.0 in Q1 2025, and up 7.14% on a QoQ basis from $126000.0 in Q4 2025.

TriSalus Life Sciences (TLSIW) has 5 years of Depreciation & Amortization (CF) data on file, last reported at $135000.0 in Q1 2026.

  • For the quarter ending Q1 2026, Depreciation & Amortization (CF) fell 21.51% year-over-year to $135000.0; the trailing twelve-month figure through Mar 2026 stood at $589000.0 (down 20.51% YoY), and the FY2025 full-year result was $626000.0, down 15.86% from the prior year.
  • Depreciation & Amortization (CF) for Q1 2026 stood at $135000.0, up from $126000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $194000.0 in Q4 2023 and bottomed at -$54000.0 in Q4 2022.
  • The 5-year median for Depreciation & Amortization (CF) is $168500.0 (2025), against an average of $152500.0.
  • The widest annual swing landed in 2023, when Depreciation & Amortization (CF) surged 459.26%; it then sank 34.72% in 2025.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at -$54000.0 in 2022, then soared by 459.26% to $194000.0 in 2023, then decreased by 0.52% to $193000.0 in 2024, then tumbled by 34.72% to $126000.0 in 2025, then rose by 7.14% to $135000.0 in 2026.
  • The last three Depreciation & Amortization (CF) figures came in at $135000.0 (Q1 2026), $126000.0 (Q4 2025), and $163000.0 (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Depreciation & Amortization (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn 381.00 Mn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn 120.00 Mn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn 749.00 Mn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn 351.00 Mn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn 40.90 Mn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn 67.10 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn 78.00 Mn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn 123.40 Mn
10 TriSalus Life Sciences - - 7.67 Mn 135,000.00

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 135,000.00
Mar 31, 2026 135,000.00
Dec 31, 2025 126,000.00
Dec 31, 2025 126,000.00
Sep 30, 2025 163,000.00
Sep 30, 2025 163,000.00
Jun 30, 2025 165,000.00
Jun 30, 2025 165,000.00
Mar 31, 2025 172,000.00
Mar 31, 2025 172,000.00
Dec 31, 2024 193,000.00
Dec 31, 2024 193,000.00
Sep 30, 2024 182,000.00
Sep 30, 2024 182,000.00
Jun 30, 2024 194,000.00
Jun 30, 2024 194,000.00
Mar 31, 2024 175,000.00
Mar 31, 2024 175,000.00
Dec 31, 2023 194,000.00
Dec 31, 2023 194,000.00
Sep 30, 2023 156,000.00
Sep 30, 2023 156,000.00
Jun 30, 2023 150,000.00
Jun 30, 2023 150,000.00
Mar 31, 2023 184,000.00
Mar 31, 2023 184,000.00
Dec 31, 2022 -54,000.00
Dec 31, 2022 -54,000.00